Fifth Third Bank (FITB) issued the following statement related to a temporary network outage this afternoon: "Earlier today we experienced a temporary outage with our network connectivity. The issue involved a simultaneous failure in both the primary system and a backup which impacted our ability to provide normal levels of service to customers. We worked closely with Cisco Systems (CSCO) to identify the issue and restore service. We are deeply sorry for the inconvenience and will make every effort to make things right for our customers who were affected."

Most recently, Francomano served as Senior Vice President, Global Head of Commercial and Medical Affairs for Stemline (STML). Prior to this, Francomano garnered extensive oncology experience operating in global roles for Baxalta, Pfizer (PFE) and GlaxoSmithKline (GSK), where he developed strategies for assets in clinical development from Phase I through Phase IV.

GOL's domestic supply increased 8.9% and demand increased by 6.3%. GOL's domestic load factor was 81.7%. The slight decrease in load factor was mainly due to GOL's discipline in yield management and some spill caused by a temporary suspension of sales on flights impacted by unscheduled aircraft maintenance. The volume of departures increased by 8.5% and seats increased by 11.6% over November 2018. GOL's international supply and demand decreased by 9.3% and 13.2% respectively, and international load factor was 72.8%. The decrease in load factor was mainly due to lower demand in Argentina and Chile. GOL's total supply was 6.4% higher due to a 11.0% increase in seats and a 7.9% increase in departures. GOL's total demand increased by 3.8% in comparison to November 2018 and consolidated load factor was 80.7%.

This estimate includes the effect of the previously announced monthly dividend of 14c per common share, payable on December 26 to holders of record on November 29, with an ex-dividend date of November 27.

In an interview on CNBC's Mad Money, Boot Barn CEO Jim Conroy said: Most of our product is still for functional use, but we've picked up in the fashionable space... We have diversified quite a bit... We are now in 33 states... We think we can double the store count... Our exclusive brands now make up about 25% of sales... We've been able to mitigate the impact of the China tariffs.

Ericsson has agreed to pay total penalties of more than $1B to resolve the government's investigation into violations of the Foreign Corrupt Practices Act arising out of the company's scheme to make and improperly record tens of millions of dollars in improper payments around the world. This includes a criminal penalty of over $520M and approximately $540M to be paid to the U.S. Securities and Exchange Commission in a related matter. An Ericsson subsidiary pleaded guilty today for its role in the scheme. Ericsson entered into a deferred prosecution agreement with the department in connection with a criminal information filed today in the Southern District of New York charging the company with conspiracies to violate the anti-bribery, books and records, and internal controls provisions of the FCPA. The Ericsson subsidiary, Ericsson Egypt Ltd, pleaded guilty today in the Southern District of New York to a one-count criminal information charging it with conspiracy to violate the anti-bribery provisions of the FCPA. The case is assigned to U.S. District Judge Alison J. Nathan of the Southern District of New York. Pursuant to its agreement with the department, Ericsson has committed to pay a total criminal penalty of $520,650,432 within 10 business days of the sentencing hearing, and has agreed to the imposition of an independent compliance monitor.

This is the lowest level of holdings since September 19th.

PICO Holdings announced that the city of El Mirage in Arizona has approved the purchase from the Company's wholly owned subsidiary, Vidler Water Company of 25,000 Long - Term Storage Credits banked in the Phoenix Active Management Area for proceeds of $8.69M, or $347.50 per Credit. Funding of the transaction is expected before December 19, 2019, and the transaction will be recorded in the Company's financial statements for the year ending December 31, 2019.

Quorum Health Corporation announced that it was notified on December 3, 2019 by the New York Stock Exchange that it was not in compliance with the NYSE's continued listing standards as a result of the average closing price of the company's common stock being less than $1.00 per share over a consecutive 30 trading-day period. As set forth in the December Notice, as of December 3, 2019, the 30 trading-day average closing share price of the company's common stock was 90c. In accordance with the NYSE rules, the company has a period of six months following the receipt of the December Notice to regain compliance with the minimum share price requirement. The company plans to notify the NYSE within 10 business days of its intent to cure the deficiency. The company can regain compliance with the minimum share price requirement at any time during the six month cure period if, on the last trading day of any calendar month during the cure period or on the last day of the cure period, the company has a closing share price of at least $1.00 and an average closing share price of at least $1.00 over the 30 trading-day period ending on such date.

Support.com trading resumes

Lockheed Martin was awarded a $153.39M cost-plus-fixed-fee modification to a previously-awarded contract. This modification procures special tooling and special test equipment required to meet current and future F-35 Lightning II low-rate initial production as well as full-rate production rates. Work is expected to be completed in December 2023. FY18, FY19 and FY20 aircraft procurement funds in the amount of $153.39M will be obligated at time of award, $39.89M of which will expire at the end of the current fiscal year. This modification combines purchases for the Air Force; Navy; Marine Corps; non-U.S DoD international partners and FMS customers. The Naval Air Systems Command is the contracting activity.

Northrop Grumman was awarded a $189M modification for the firm-fixed-price portion of a previously-awarded contract. This modification is for the purchase of six Gallium Nitride full-rate-production systems and associated travel in support of Program Executive Officer Land Systems, Quantico, Virginia. Work will be performed in Linthicum, Maryland and is expected to be complete by April 4, 2023. FY20 procurement funds for $189M will be obligated at the time of award and will not expire at the end of the current fiscal year. The contract modification was not competitively procured. The base contract was prepared in accordance with Federal Acquisition Regulation 6.302-1 and 10 U.S. Code Section 2304. The Marine Corps Systems Command is the contracting activity.

The record date for the special distribution is December 17, and the payment date for the distribution is December 26. This is a part of the ongoing capital allocation review being conducted by the Board.

Support.com trading halted, news dissemination

Alector reported safety and biomarker data from the single ascending dose phase of the INVOKE Phase1 study of its product candidate, AL002, in healthy volunteers. AL002 is a monoclonal antibody intended to enhance the activity of TREM2 and is being developed by Alector for the treatment of Alzheimer's disease in collaboration with its partner AbbVie. The data were presented today at the 12th Clinical Trials on Alzheimer's Disease meeting being held December 4-6 in San Diego, California. The AL002 presentation at CTAD showcases the first data in humans showing that a TREM2 activating antibody engages its target and demonstrates downstream activity in the CNS. Robert Paul, M.D., Ph.D., chief medical officer of Alector, presented an abstract entitled, A Phase 1 Study of AL002 in Healthy Volunteers and Patients With Mild-To-Moderate Alzheimer's Disease during an oral communications session. The INVOKE clinical study is a first-in-human study in healthy adults and in patients with mild to moderate Alzheimer's disease, designed to assess the safety and tolerability, pharmacokinetics, and pharmacodynamics of AL002. The data reported today are from the study's SAD phase in 56 healthy adults, who were enrolled into nine escalating dose cohorts. Summary of the clinical data of the SAD portion of the Phase 1 INVOKE clinical study presented at CTAD: 56 healthy volunteers were treated with nine escalating doses of AL002; AL002 was found to be generally safe and well-tolerated; AL002 reduced cerebrospinal fluid soluble TREM2 in a dose-dependent manner, demonstrating proof-of-target engagement in the brain; AL002 elevated a biomarker for microglia activity in the CSF, indicating proof-of-mechanism; the Phase 1b portion of the study in Alzheimer's disease patients is on-going. Alector expects to initiate the AL002 Phase 2, proof-of-concept study in 2020. "Loss of TREM2 activity has been shown through human genetics to be one of the major risk factors of developing Alzheimer's disease," said Robert Paul, M.D., Ph.D., chief medical officer of Alector. "AL002 is the first TREM2 agonistic antibody in clinical development for Alzheimer's disease, and we are pleased to see safety and tolerability in healthy volunteers and that AL002 is showing proof-of-target engagement and proof-of-mechanism at this early stage in development. These results together will help guide our dose selection for the Phase 2 study in Alzheimer's patients."

On December 2,Craig Allen informed America First Multifamily Investors of his intent to retire and leave the Partnership in his capacity as its CFO on December 31, 2019. On December 6, 2019, the Board appointed Jesse Coury, the Partnership's current Corporate Controller, to serve as the Partnership's interim CFO, effective on January 1, 2020. Mr. Coury will serve in this capacity until a permanent CFO is appointed.

The Board of Directors of PNM Resources unanimously voted to increase the company's annual dividend payment by 7c, a 6% increase, to an indicated annual rate of $1.23 per share of common stock. This is consistent with the company's target to pay out 50%-60% of annual ongoing earnings. The board has declared the resulting quarterly stock dividend of 30.75c per share, payable February 14, 2020, to shareholders of record at the close of business February 3, 2020.